70 related articles for article (PubMed ID: 17391964)
1. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators.
Hu B; Jetter J; Kaufman D; Singhaus R; Bernotas R; Unwalla R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Liu QY; Feingold I; Huselton C; Azam F; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2007 May; 15(10):3321-33. PubMed ID: 17391964
[TBL] [Abstract][Full Text] [Related]
2. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Hu B; Collini M; Unwalla R; Miller C; Singhaus R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Resmini C; Liu QY; Feingold I; Huselton C; Azam F; Farnegardh M; Enroth C; Bonn T; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
J Med Chem; 2006 Oct; 49(21):6151-4. PubMed ID: 17034119
[TBL] [Abstract][Full Text] [Related]
3. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
[TBL] [Abstract][Full Text] [Related]
4. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
[TBL] [Abstract][Full Text] [Related]
5. Biarylether amide quinolines as liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Ullrich J; Fletcher H; Quinet E; Nambi P; Unwalla R; Wilhelmsson A; Goos-Nilsson A; Farnegardh M; Wrobel J
Bioorg Med Chem; 2009 Feb; 17(4):1663-70. PubMed ID: 19162487
[TBL] [Abstract][Full Text] [Related]
6. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
[TBL] [Abstract][Full Text] [Related]
7. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a).
Menke JG; Macnaul KL; Hayes NS; Baffic J; Chao YS; Elbrecht A; Kelly LJ; Lam MH; Schmidt A; Sahoo S; Wang J; Wright SD; Xin P; Zhou G; Moller DE; Sparrow CP
Endocrinology; 2002 Jul; 143(7):2548-58. PubMed ID: 12072387
[TBL] [Abstract][Full Text] [Related]
8. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.
Washburn DG; Hoang TH; Campobasso N; Smallwood A; Parks DJ; Webb CL; Frank KA; Nord M; Duraiswami C; Evans C; Jaye M; Thompson SK
Bioorg Med Chem Lett; 2009 Feb; 19(4):1097-100. PubMed ID: 19167885
[TBL] [Abstract][Full Text] [Related]
11. N-heterocyclic derived M1 positive allosteric modulators.
Kuduk SD; Di Marco CN; Cofre V; Pitts DR; Ray WJ; Ma L; Wittmann M; Veng L; Seager MA; Koeplinger K; Thompson CD; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2010 Feb; 20(4):1334-7. PubMed ID: 20097564
[TBL] [Abstract][Full Text] [Related]
12. SAR studies: designing potent and selective LXR agonists.
Szewczyk JW; Huang S; Chin J; Tian J; Mitnaul L; Rosa RL; Peterson L; Sparrow CP; Adams AD
Bioorg Med Chem Lett; 2006 Jun; 16(11):3055-60. PubMed ID: 16529931
[TBL] [Abstract][Full Text] [Related]
13. Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor.
Narlawar R; Baumann K; Czech C; Schmidt B
Bioorg Med Chem Lett; 2007 Oct; 17(19):5428-31. PubMed ID: 17723298
[TBL] [Abstract][Full Text] [Related]
14. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Liu W; Chen S; Dropinski J; Colwell L; Robins M; Szymonifka M; Hayes N; Sharma N; MacNaul K; Hernandez M; Burton C; Sparrow CP; Menke JG; Singh SB
Bioorg Med Chem Lett; 2005 Oct; 15(20):4574-8. PubMed ID: 16125384
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
Panday N; Benz J; Blum-Kaelin D; Bourgeaux V; Dehmlow H; Hartman P; Kuhn B; Ratni H; Warot X; Wright MB
Bioorg Med Chem Lett; 2006 Oct; 16(19):5231-7. PubMed ID: 16876993
[TBL] [Abstract][Full Text] [Related]
17. The liver X receptor and atherosclerosis.
Scott J
N Engl J Med; 2007 Nov; 357(21):2195-7. PubMed ID: 18032771
[No Abstract] [Full Text] [Related]
18. 2-Aryl-N-acyl indole derivatives as liver X receptor (LXR) agonists.
Kher S; Lake K; Sircar I; Pannala M; Bakir F; Zapf J; Xu K; Zhang SH; Liu J; Morera L; Sakurai N; Jack R; Cheng JF
Bioorg Med Chem Lett; 2007 Aug; 17(16):4442-6. PubMed ID: 17587573
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
[TBL] [Abstract][Full Text] [Related]
20. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver.
Anderson SP; Dunn C; Laughter A; Yoon L; Swanson C; Stulnig TM; Steffensen KR; Chandraratna RA; Gustafsson JA; Corton JC
Mol Pharmacol; 2004 Dec; 66(6):1440-52. PubMed ID: 15371561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
